Kawa S, Tokoo M, Oguchi H, Furuta S, Homma T, Hasegawa Y, Ogata H, Sakata K
Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Pancreas. 1994 Nov;9(6):692-7. doi: 10.1097/00006676-199411000-00003.
Epitope analysis of SPan-1 and DUPAN-2 was compared with that of CA19-9 using the synthesized glycoconjugate sialyllacto-N-fucopentaose II (SLF II, sialyl-Lewis(a)) and its precursor, sialyllact-N-tetraose (LSTa, sialyl-Lewis(c)), conjugated to human serum albumin. The CA19-9 and DUPAN-2 assay systems specifically recognized SLF II and LSTa, respectively. The SPan-1 assay system recognized both SLF II and LSTa, although the reactivity with the former was far stronger than that with the latter. These results were, in general, compatible with those obtained from assaying these markers in the sera of two pancreatic cancer patients with definite Lewis-negative phenotype and in the sera of 39 CA19-9-negative pancreatic cancer patients. In conclusion, DUPAN-2 is the precursor of CA19-9 and is accumulated in the sera of pancreatic cancer patients with Lewis-negative phenotype and SPan-1 has an advantage over CA19-9 in the diagnosis of patients with Lewis-negative phenotype, although both markers have almost the same sensitivity for this malignancy.
使用与人血清白蛋白偶联的合成糖缀合物唾液酸化乳糖-N-岩藻戊糖II（SLF II，唾液酸化Lewis(a)）及其前体唾液酸化乳糖-N-四糖（LSTa，唾液酸化Lewis(c)），对SPan-1和DUPAN-2的表位分析与CA19-9的表位分析进行了比较。CA19-9和DUPAN-2检测系统分别特异性识别SLF II和LSTa。SPan-1检测系统识别SLF II和LSTa两者，尽管与前者的反应性远强于与后者的反应性。总体而言，这些结果与在两名具有明确Lewis阴性表型的胰腺癌患者血清以及39名CA19-9阴性胰腺癌患者血清中检测这些标志物所获得的结果相符。总之，DUPAN-2是CA19-9的前体，在具有Lewis阴性表型的胰腺癌患者血清中蓄积，并且在Lewis阴性表型患者的诊断中，SPan-1比CA19-9具有优势，尽管这两种标志物对这种恶性肿瘤的敏感性几乎相同。
Zotero 插件